Cardioversion for atrial fibrillation: Treatment options and advances

PACE - Pacing and Clinical Electrophysiology

Volumn 32, Issue 8, 2009, Pages 1073-1084

  Reiffel, James A ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

Antiarrhythmia drugs; Cardioversion; Fibrillation; Rhythm control

Indexed keywords

ACETYLSALICYLIC ACID; AMIODARONE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIGITALIS; DISOPYRAMIDE; DOFETILIDE; DRONEDARONE; ENOXAPARIN; FLECAINIDE; HEPARIN; IBUTILIDE; ION CHANNEL; MAGNESIUM SULFATE; PLACEBO; PROCAINAMIDE; PROPAFENONE; QUINIDINE; SOTALOL; STEROID; VERNAKALANT; WARFARIN;

BLISTER; BRADYCARDIA; BURN; CARDIOVERSION; CATHETER ABLATION; CLINICAL TRIAL; COMPARATIVE STUDY; CONSTIPATION; DRUG EFFICACY; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL DISEASE; GASTROINTESTINAL SYMPTOM; HEART ARRHYTHMIA; HEART ATRIUM; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HEART RATE; HEART RHYTHM; HEART VENTRICLE; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE TACHYCARDIA; HUMAN; HYPOTENSION; LUNG EDEMA; MORBIDITY; MORTALITY; PHLEBITIS; QT PROLONGATION; RECOMMENDED DRUG DOSE; REVIEW; RISK; SINUS ARREST; SINUS RHYTHM; STROKE; SUPRAVENTRICULAR PREMATURE BEAT; SYMPTOM; THROMBOEMBOLISM; TORSADE DES POINTES; TRANSIENT ISCHEMIC ATTACK; TREATMENT CONTRAINDICATION;

ATRIAL FIBRILLATION; DEFIBRILLATORS, IMPLANTABLE; ELECTRIC COUNTERSHOCK; FORECASTING; HUMANS; TECHNOLOGY ASSESSMENT, BIOMEDICAL; THERAPY, COMPUTER-ASSISTED;

EID: 68449101941     PISSN: 01478389     EISSN: 15408159     Source Type: Journal    
DOI: 10.1111/j.1540-8159.2009.02441.x     Document Type: Review

References (87)

1. Fuster V, Rydén LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, Halperin JL, et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): Developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 2006 114 : e257 e354.
2. Go AS, Hylek EM, Phillips KA, Chang YC, Henault LE, Selby JV, Singer DE. Prevalence of diagnosed atrial fibrillation in adults. National implications for rhythm management and stroke prevention: The Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001 285 : 2370 2375.
3. Miyasaka Y, Barnes ME, Gersh BJ, Cha SS, Bailey KR, Abhayaratna WP, Seward JB, et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation 2006 114 : 119 125.
4. Stroke Risk in Atrial Fibrillation Working Group. Independent predictors of stroke in patients with atrial fibrillation. A systematic review. Neurology 2007 69 : 546 554.
5. Krahn AD, Manfreda J, Tate RB, Mathewson FAL, Cuddy TE. The natural history of atrial fibrillation: Incidence, risk factors, and prognosis in the Manitoba follow-up study. Am J Med 1995 98 : 476 484.
6. Maggioni AP, Latini R, Carson PE, Singh SN, Barlera S, Glazer R, Masson S, et al. Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: Results from the Valsartan Heart Failure Trial (Val-HeFT). Am Heart J 2005 149 : 548 557.
7. Stewart S, MacIntyre K, Chalmers JWT, Boyd J, Finlayson A, Redpath A, Pell JP, et al. Trends in case-fatality in 22,968 patients admitted for the first time with atrial fibrillation in Scotland, 1986-1995. Int J Cardiol 2002 82 : 229 236.
8. Dorian P, Jung W, Newman D, Paquette M, Wood K, Ayers GM, Camm J, et al. The impairment of health-related quality of life in patients with intermittent atrial fibrillation: Implications for the assessment of investigational therapy. J Am Coll Cardiol 2000 36 : 1303 1309.
9. Cordina J, Mead G. Pharmacological cardioversion for atrial fibrillation and flutter (review). Cochrane Database Syst Rev 2005 2 : CD003713. doi: 10.1002/14651858. CD003713.pub2.
10. Wyse DG, Waldo AL, DiMarco JP, Domanski MJ, Rosenberg Y, Schron EB, Kellen JC, et al Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002 347 : 1825 1833.
11. Carlsson J, Miketic S, Windeler J, Cuneo A, Haun S, Micus S, Walter S, et al STAF Investigators. Randomized trial of rate-control versus rhythm-control in persistent atrial fibrillation. The Strategies of Treatment of Atrial Fibrillation (STAF) Study. J Am Coll Cardiol 2003 41 : 1690 1696. (Pubitemid 36584236)
12. Hohnloser SH, Kuck K-H, Lilienthal J PIAF Investigators. Rhythm or rate control in atrial fibrillation - pharmacological intervention in atrial fibrillation (PIAF): A randomised trial. Lancet 2000 356 : 1789 1794.
13. Opolski G, Torbicki A, Kosior DA, Szulc M, Wożakowska-Kapłon B, Kołodziej P, Achremczyk P Investigators of the Polish HOT CAFE Trial. Rate control vs rhythm control in patients with nonvalvular persistent atrial fibrillation: The results of the Polish How to Treat Chronic Atrial Fibrillation (HOT CAFE) study. Chest 2004 126 : 476 486.
14. Van Gelder IC, Hagens VE, Bosker HA, Kingma JH, Kamp O, Kingma T, Said SA, et al Rate Control Versus Electrical Cardioversion for Persistent Atrial Fibrillation Study Group. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med 2002 347 : 1834 1840.
15. Roy D, Talajic M, Nattel S, Wyse DG, Dorian P, Lee KL, Bourassa MG, et al Atrial Fibrillation and Congestive Heart Failure Investigators. Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med 2008 358 : 2667 2677.
16. Andrews M, Nelson BP. Atrial fibrillation. Mt Sinai J Med 2006 73 : 482 492.
17. Testa L, Biondi-Zoccai GGL, Dello Russo A, Bellocci F, Andreotti F, Crea F. Rate-control vs. rhythm-control in patients with atrial fibrillation: A meta-analysis. Eur Heart J 2005 26 : 2000 2006.
18. Crijns HJGM. Rate versus rhythm control in patients with atrial fibrillation. What the trials really say. Drugs 2005 65 : 1651 1667.
19. AFFIRM Investigators. Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) study. Circulation 2004 109 : 1509 1513.
20. Pedersen OD, Bagger H, Keller N, Marchant B, Køber L, Torp-Pedersen C. Efficacy of dofetilide in the treatment of atrial fibrillation-flutter in patients with reduced left ventricular function: A Danish Investigations of Arrhythmia and Mortality ON Dofetilide (DIAMOND) substudy. Circulation 2001 104 : 292 296.
21. Hagens VE, Crijns HJGM, Van Veldhuisen DJ, Van Den Berg MP, Rienstra M, Ranchor AV, Bosker HA, et al Rate Control versus Electrical Cardioversion for Persistent Atrial Fibrillation Study Group. Rate control versus rhythm control for patients with persistent atrial fibrillation with mild to moderate heart failure: Results from the Rate Control versus Electrical Cardioversion (RACE) study. Am Heart J 2005 149 : 1106 1111. (Pubitemid 40848157)
22. Costeas C, Kassotis J, Blitzer M, Reiffel JA. Rhythm management in atrial fibrillation - with a primary emphasis on pharmacological therapy: Part 2. Pacing Clin Electrophysiol 1998 21 : 742 752.
23. Joglar JA, Kowal RC. Electrical cardioversion of atrial fibrillation. Cardiol Clin 2004 22 : 101 111.
24. McNamara RL, Tamariz LJ, Segal JB, Bass EB. Management of atrial fibrillation: Review of the evidence for the role of pharmacologic therapy, electrical cardioversion, and echocardiography. Ann Intern Med 2003 139 : 1018 1033.
25. Hwang G-S, Tang L, Joung B, Morita N, Hayashi H, Karagueuzian HS, Weiss JN, et al. Superiority of biphasic over monophasic defibrillation shocks is attributable to less intracellular calcium transient heterogeneity. J Am Coll Cardiol 2008 52 : 828 835.
26. Mittal S, Stein KM, Markowitz SM, Iwai S, Guttigoli A, Lerman BB. An update on electrical cardioversion of atrial fibrillation. Card Electrophysiol Rev 2003 7 : 285 289.
27. Glover BM, McCann CJ, Manoharan G, Walsh SJ, Moore MJ, Allen JD, Escalona JD, et al. A pilot study of a low-tilt biphasic waveform for transvenous cardioversion of atrial fibrillation: Improved efficacy compared with conventional capacitor-based waveforms in patients. Pacing Clin Electrophysiol 2008 31 : 1020 1024.
28. Raitt MH, Volgman AS, Zoble ZG, Charbonneau L, Padder FA, O'Hara GE, Kerr D AFFIRM Investigators. Prediction of the recurrence of atrial fibrillation after cardioversion in the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study. Am Heart J 2006 151 : 390 396.
29. Blich M, Edoute Y. Electrical cardioversion for persistent or chronic atrial fibrillation: Outcome and clinical factors predicting short and long term success rate. Int J Cardiol 2006 107 : 389 394.
30. Page RL, Kerber RE, Russell JK, Trouton T, Waktare J, Gallik D, Olgin JE, et al BiCard Investigators. Biphasic versus monophasic shock waveform for conversion of atrial fibrillation. The results of an international randomized, double-blind, multicenter trial. J Am Coll Cardiol 2002 39 : 1956 1963.
31. Sarubbi B, Ducceschi V, D'Andrea A, Liccardo B, Santangelo L, Iacono A. Atrial fibrillation: What are the effects of drug therapy on the effectiveness and complications of electrical cardioversion? Can J Cardiol 1998 14 : 1267 1273.
32. Snow V, Weiss KB, LeFevre M, McNamara R, Bass E, Green LA, Michl K, et al Joint AAFP/ACP Panel on Atrial Fibrillation. Management of newly detected atrial fibrillation: A clinical practice guideline from the American Academy of Family Physicians and the American College of Physicians. Ann Intern Med 2003 139 : 1009 1017.
33. Waller C, Callies F, Langenfeld H. Adverse effects of direct current cardioversion on cardiac pacemakers and electrodes. Is external cardioversion contraindicated in patients with permanent pacing systems? Europace 2004 6 : 165 168.
34. Alegret JM, Viñolas X, Sagristá J, Hernandez-Madrid A, Pérez L, Sabaté X, Mont L. Predictors of success and effect of biphasic energy on electrical cardioversion in patients with persistent atrial fibrillation. Europace 2007 9 : 942 946.
35. Joglar JA, Hamdan MH, Ramaswamy K, Zagrodsky JD, Sheehan CJ, Nelson LL, Andrews TC. Initial energy for elective external cardioversion of persistent atrial fibrillation. Am J Cardiol 2000 86 : 348 350.
36. Upshaw CB Jr. Hemodynamic changes after cardioversion of chronic atrial fibrillation. Arch Intern Med 1997 157 : 1070 1076.
37. Perrin L, Schmartz D, Ducart A, Koch M, Dejonckheere M. Etomidate and left ventricular systolic function: An echographic study. Abstract presented at: 2007 American Society of Anesthesiologists Annual Meeting; October 13, 2007 San Francisco, CA. Abstract A298.
38. Nergårdh AK, Rosenqvist M, Frick M. Self-limited bursts of atrial fibrillation following successful cardioversion. Int J Cardiol 2007 119 : 95 100.
39. Gallagher MM, Hennessy BJ, Edvardsson N, Hart CM, Shannon MS, Obel OA, Al-Saady NM, et al. Embolic complications of direct current cardioversion of atrial arrhythmias: Association with low intensity of anticoagulation at the time of cardioversion. J Am Coll Cardiol 2002 40 : 926 933.
40. Freestone B, Chong AY, Blann AD, Lip GYH. The effects of direct current cardioversion for persistent atrial fibrillation on indices of endothelial damage/dysfunction. Thromb Res 2006 118 : 479 485.
41. Klein AL, Grimm RA, Murray RD, Apperson-Hansen C, Asinger RW, Black IW, Davidoff R, et al. Use of transeosphageal echocardiography to guide cardioversion in patients with atrial fibrillation. N Engl J Med 2001 344 : 1411 1420.
42. Klein AL, Jasper SE, Katz WE, Malouf JF, Pape LA, Stoddard MF, Aperson-Hansen C, et al. The use of enoxaparin compared with unfractionated heparin for short-term antithrombotic therapy in atrial fibrillation patients undergoing transoesophageal echocardiography-guided cardioversion: Assessment of Cardioversion Using Transoesophageal Echocardiography (ACUTE) II randomized multicentre study. Eur Heart J 2006 27 : 2858 2865.
43. Gowda RM, Misra D, Khan IA, Schweitzer P. Acute pulmonary edema after cardioversion of cardiac arrhythmias. Int J Cardiol 2003 92 : 293 296.
44. Stroobandt R, Stiels B, Hoebrechts R Propafenone Atrial Fibrillation Trial Investigators. Propafenone for conversion and prophylaxis of atrial fibrillation. Am J Cardiol 1997 79 : 418 423.
45. Bianconi L, Mennuni M, Lukic V, Castro A, Chieffi M, Santini M. Effects of oral propafenone administration before electrical cardioversion of chronic atrial fibrillation: A placebo-controlled study. J Am Coll Cardiol 1996 28 : 700 706.
46. Nergärdh A, Nordlander R, Frick M. Rate of conversion and recurrence after sotalol treatment in patients with direct current-refractory atrial fibrillation. Clin Cardiol 2006 29 : 56 60.
47. Saliba W, Juratli N, Chung MK, Niebauer MJ, Erdogan O, Trohman R, Wilkoff BL, et al. Higher energy synchronized external direct current cardioversion for refractory atrial fibrillation. J Am Coll Cardiol 1999 34 : 2031 2034.
48. Van Gelder IC, Tuinenburg AE, Schoonderwoerd BS, Tieleman RG, Crijns HJGM. Pharmacologic versus direct-current electrical cardioversion of atrial flutter and fibrillation. Am J Cardiol 1999 84 : 147R 151R.
49. Lévy S. Monitoring after cardioversion of atrial fibrillation. In : Malik M, Camm AJ (eds Dynamic Electrocardiography. Armonk, NY, Futura Publishing, Inc., 2004, pp. 506 510.
50. Dell'Orfano JT, Luck JC, Wolbrette DL, Patel H, Naccarelli GV. Drugs for conversion of atrial fibrillation. Am Fam Physician 1998 58 : 471 480.
51. Lafuente-Lafuente C, Mouly S, Longas-Tejero MA, Bergmann JF. Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation. Cochrane Database Syst Rev 2007 4 : CD005049. doi: 10.1002/14651858. CD005049.pub 2.
52. Alboni P, Botto GL, Baldi N, Luzi M, Russo V, Gianfranchi L, Marchi P, et al. Outpatient treatment of recent-onset atrial fibrillation with the "pill-in-the-pocket" approach. N Engl J Med 2004 351 : 2384 2391.
53. Boriani G, Capucci A, Lenzi T, Sanguinetti M, Magnani B. Propafenone for conversion of recent-onset atrial fibrillation. A controlled comparison between oral loading dose and intravenous administration. Chest 1995 108 : 355 358.
54. Howard PA. Ibutilide: An antiarrhythmic agent for the treatment of atrial fibrillation or flutter. Ann Pharmacother 1999 33 : 38 47.
55. VanderLugt JT, Mattioni T, Denker S, Torchiana D, Ahern T, Wakefield LK, Perry KT, et al. Efficacy and safety of ibutilide fumarate for the conversion of atrial arrhythmias after cardiac surgery. Circulation 1999 100 : 369 375.
56. Abi-Mansour P, Carberry PA, McCowan RJ, Henthorn RW, Dunn GH, Perry KT Study Investigators. Conversion efficacy and safety of repeated doses of ibutilide in patients with atrial flutter and atrial fibrillation. Am Heart J 1998 136 : 632 642.
57. Hersi A, Wyse DG. Management of atrial fibrillation. Curr Probl Cardiol 2005 30 : 175 234.
58. Tercius AJ, Kluger J, Coleman CI, White CM. Intravenous magnesium sulfate enhances the ability of intravenous ibutilide to successfully convert atrial fibrillation or flutter. Pacing Clin Electrophysiol 2007 30 : 1331 1335.
59. Lombardi F, Terranova P. Pharmacological treatment of atrial fibrillation: Mechanisms of action and efficacy of class III drugs. Curr Med Chem 2006 13 : 1635 1653.
60. Fragakis N, Papadopoulos N, Papanastasiou S, Kozirakis M, Maligkos G, Tsaritsaniotis E, Katsaris G. Efficacy and safety of ibutilide for cardioversion of atrial flutter and fibrillation in patients receiving amiodarone or propafenone. Pacing Clin Electrophysiol 2005 28 : 954 961.
61. Boriani G, Biffi M, Capucci A, Botto GL, Broffoni T, Rubino I, Della Casa S, et al. Oral propafenone to convert recent-onset atrial fibrillation in patients with and without underlying heart disease. A randomized, controlled trial. Ann Intern Med 1997 126 : 621 625.
62. Khan IA. Single oral loading dose of propafenone for pharmacological cardioversion of recent-onset atrial fibrillation. J Am Coll Cardiol 2001 37 : 542 547.
63. Reiffel JA. Efficacy and safety of extra class IC doses for pharmacologic cardioversion in patients maintained on class IC drugs for atrial fibrillation. J Am Coll Cardiol 2006 47 : 309A 310A. Abstract 938-200.
64. Singh S, Zoble RG, Yellen L, Brodsky MA, Feld GK, Berk M, Billing CB Jr. Dofetilide Atrial Fibrillation Investigators. Efficacy and safety of oral dofetilide in converting to and maintaining sinus rhythm in patients with chronic atrial fibrillation or atrial flutter: The Symptomatic Atrial Fibrillation Investigative Research on Dofetilide (SAFIRE-D) study. Circulation 2000 102 : 2385 2390.
65. Zimetbaum P. Amiodarone for atrial fibrillation. N Engl J Med 2007 356 : 935 941.
66. Roy D, Pratt CM, Torp-Pedersen C, Wyse DG, Toft E, Juul-Moller S, Nielsen T, et al Atrial Arrhythmia Conversion Trial Investigators. Vernakalant hydrochloride for rapid conversion of atrial fibrillation: A phase 3, randomized, placebo-controlled trial. Circulation 2008 117 : 1518 1525.
67. Kowey PR, Roy D, Pratt CM, Schwartz PJ, Dorian P, Mitchell LB, Toft E. Efficacy and safety of vernakalant hydrochloride injection for the treatment of atrial fibrillation after valvular coronary artery bypass surgery. Circulation 2007 116 : II-636 II-637. Abstract 2860.
68. Cotiga D, Arshad A, Aziz E, Joshi S, Koneru JN, Steinberg JS. Acute conversion of persistent atrial fibrillation during dofetilide initiation. Pacing Clin Electrophysiol 2007 30 : 1527 1530.
69. Galve E, Ruis T, Ballester R, Araza MA, Arnau JM, Garcia-Dorado D, Soler-Soler J, et al. Intravenous amiodarone in treatment of recent-onset atrial fibrillation: Results of a randomized, controlled study. J Am Coll Cardiol 1996 27 : 1079 1082.
70. Cybulski J, Kulakowski P, Budaj A, Danielewicz H, Maciejewicz J, Kawka-Urbanek T, Ceremuzynski L. Intravenous amiodarone for cardioversion of recent-onset atrial fibrillation. Clin Cardiol 2003 26 : 329 335.
71. Chevalier P, Durand-Dubief A, Burri H, Cucherat M, Kirkorian G, Touboul P. Amiodarone versus placebo and class IC drugs for cardioversion of recent-onset atrial fibrillation: A meta-analysis. J Am Coll Cardiol 2003 41 : 255 262.
72. Reiffel JA. Intravenous amiodarone in the management of atrial fibrillation. J Cardiovasc Pharmacol Ther 1999 4 : 199 204.
73. Khan IA, Mehta NJ, Gowda RM. Amiodarone for pharmacological cardioversion of recent-onset atrial fibrillation. Int J Cardiol 2003 89 : 239 248.
74. Singh BN, Connolly SJ, Crijns HJ, Roy D, Kowey PR, Capucci A, Radzik D, et al EURIDIS and ADONIS Investigators. Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter. N Engl J Med 2007 357 : 987 999.
75. Goldstein RN, Stambler BS. New antiarrhythmic drugs for prevention of atrial fibrillation. Prog Cardiovasc Dis 2005 48 : 193 208.
76. KAch class IC drugs and beta blockers in pigs. Med Sci Monit 2004 10 : BR221 BR228.
77. Fedida D, Orth PMR, Chen JYC, Lin S, Plouvier B, Jung G, Ezrin AM, et al. The mechanism of atrial antiarrhythmic action of RSD1235. J Cardiovasc Electrophysiol 2005 16 : 1227 1238.
78. Dorian P, Pinter A, Mangat I, Korley V, Cvitkovic SS, Beatch GN. The effect of vernakalant (RSD1235), an investigational antiarrhythmic agent, on atrial electrophysiology in humans. J Cardiovasc Pharmacol 2007 50 : 35 40.
79. Goldstein RN, Khrestian C, Carlsson L, Waldo AL. AZD7009: A new antiarrhythmic drug with predominant effects on the atria effectively terminates and prevents reinduction of atrial fibrillation and flutter in the sterile pericarditis model. J Cardiovasc Electrophysiol 2004 15 : 1444 1450.
80. Dobrev D. Electrical remodeling in atrial fibrillation. Herz 2006 31 : 108 112.
81. Duytschaever M, Blaauw Y, Allessie M. Consequences of atrial electrical remodeling for the anti-arrhythmic action of class IC and class III drugs. Cardiovasc Res 2005 67 : 69 76.
82. Blaauw Y, Gögelein H, Tieleman RG, van Hunnik A, Schotten U, Allessie MA. "Early" class III drugs for the treatment of atrial fibrillation: Efficacy and atrial selectivity of AVE0118 in remodeled atria of the goat. Circulation 2004 110 : 1717 1724.
83. Kr blockers dofetilide, azimilide, d,l-sotalol and ibutilide. Naunyn Schmiedebergs Arch Pharmacol 2002 366 : 482 487.
84. Li D, Zhang L, Kneller J, Nattel S. Potential ionic mechanism for repolarization differences between canine right and left atrium. Circ Res 2001 88 : 1168 1175.
85. Camm AJ, Wang J, Kitt TM. Cardiac rhythm safety of vernakalant hydrochloride injection in the 24-hour postdose period in patients with atrial fibrillation or atrial flutter. Heart Rhythm 2009 5 : S128 S129.
86. Na and suppresses early afterdepolarizations and torsades de pointes induced by class III agents. Cardiovasc Res 2006 70 : 486 496.
87. Wettwer E, Christ T, Dobrev D, Ravens U. Novel anti-arrhythmic agents for the treatment of atrial fibrillation. Curr Opin Pharmacol 2007 7 : 214 218.